RENOVARO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.53 USD | -10.00% |
|
-29.49% | -51.74% |
| Apr. 24 | Renovaro's RenovaroCube Amends Agreement to Acquire 100% Stake in Cyclomics | MT |
| Apr. 18 | Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board | CI |
Valuation
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 120.1 | 174.6 | 195.8 | 258.2 | 102.2 | 34.41 |
| Enterprise Value (EV) 1 | 104.5 | 162.3 | 194.6 | 244.9 | 100.2 | 38.32 |
| P/E ratio | -7.83 x | -9.38 x | -17.1 x | -8.77 x | -0.89 x | -0.8 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -32.9 x | -14.9 x | -16.5 x | -10.5 x | -4.41 x | -1.97 x |
| EV / FCF | -157 x | -31.4 x | -29.6 x | -19.9 x | -18.2 x | -4.84 x |
| FCF Yield | -0.64% | -3.18% | -3.38% | -5.02% | -5.5% | -20.7% |
| Price to Book | 0.77 x | 1.18 x | 1.18 x | 1.49 x | 1.41 x | 0.78 x |
| Nbr of stocks (in thousands) | 36,164 | 38,789 | 46,497 | 51,952 | 52,950 | 60,738 |
| Reference price 2 | 3.320 | 4.500 | 4.210 | 4.970 | 1.930 | 0.5666 |
| Announcement Date | 10/1/18 | 9/30/19 | 9/23/20 | 9/24/21 | 2/27/23 | 10/2/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -3.171 | -10.92 | -11.82 | -23.28 | -22.7 | -19.48 |
| EBIT 1 | -6.03 | -10.99 | -11.92 | -23.4 | -22.83 | -19.6 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -9.264 | -18.02 | -11.42 | -26.85 | -113.4 | -39.68 |
| Net income 1 | -9.152 | -18.02 | -11.42 | -26.72 | -113.4 | -39.68 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.4241 | -0.4798 | -0.2464 | -0.5666 | -2.159 | -0.7053 |
| Free Cash Flow 1 | -0.666 | -5.164 | -6.57 | -12.3 | -5.514 | -7.919 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 10/1/18 | 9/30/19 | 9/23/20 | 9/24/21 | 2/27/23 | 10/2/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 3.9 |
| Net Cash position 1 | 15.6 | 12.3 | 1.11 | 13.3 | 1.99 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.2004 x |
| Free Cash Flow 1 | -0.67 | -5.16 | -6.57 | -12.3 | -5.51 | -7.92 |
| ROE (net income / shareholders' equity) | -11.6% | -10.9% | -6.73% | -15.7% | -91.7% | -66.6% |
| ROA (Net income/ Total Assets) | -4.09% | -3.79% | -4.16% | -7.96% | -10.4% | -17.1% |
| Assets 1 | 223.6 | 475.3 | 274.2 | 335.9 | 1,090 | 231.6 |
| Book Value Per Share 2 | 4.310 | 3.820 | 3.580 | 3.340 | 1.370 | 0.7300 |
| Cash Flow per Share 2 | 0.4300 | 0.2700 | 0.1900 | 0.4000 | 0.1700 | 0.0300 |
| Capex 1 | 0.03 | 0.72 | 0.18 | 0.05 | 0.01 | 0.03 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 10/1/18 | 9/30/19 | 9/23/20 | 9/24/21 | 2/27/23 | 10/2/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -51.74% | 220M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RENB Stock
- Financials Renovaro Inc.
